Mesoblast (AU: MSB)

Last close As at 20/06/2024

0.93

0.23 (32.86%)

Market capitalisation

605m

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | edison tv

Mesoblast: Edison Open House Healthcare 2022

Healthcare | Update

Mesoblast — A significant impact on back pain

Healthcare | edison tv

Mesoblast – Edison Open House interview

Healthcare | Update

Mesoblast — Novartis licenses ARDS program

Sector

Healthcare

Balance Sheet

Forecast net cash (US$m)

16.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 36.8 (12.3) (53.5)
Relative 27.6 (7.6) (50.0)
52 week high/low A$2.0/A$0.6

Financials

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 31.6 (64.8) (79.6) (13.28) N/A N/A
2021A 7.4 (89.3) (104.3) (17.09) N/A N/A
2022E 8.6 (83.2) (92.6) (14.29) N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Mesoblast — Update 28 February 2017

Update

Healthcare

Mesoblast — Update 21 September 2016

Outlook

Healthcare

Mesoblast — Update 8 July 2016

Update

Healthcare

Mesoblast — Update 11 May 2016

Update

Healthcare

Mesoblast — Update 17 February 2016

Update

Healthcare

Mesoblast — Update 24 January 2016

thematic

Healthcare

Machine learning in drug development

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?